drugset / Trial / NCT01123811
Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Based on the current promising results with irinotecan and cetuximab in patients with recurrent metastatic colorectal cancer, and the excellent results of Irinotecan and 5-FU in gastric cancer , the present clinical study to evaluate the overall response rate, the time to progression and the overall survival of the combined treatment of cetuximab and irinotecan and 5-FU in patients with esophagogastric cancer is urgently needed.
Timeline
- Start
- 2006-05
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Background | Irinotecan | Small molecule | 80 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 200 mg/m2 | — |
| Background | fluorouracil | Small molecule | 1500 mg/m2 | — |